| Literature DB >> 32545813 |
Dmitry D Evtyugin1, Sandra Magina1, Dmitry V Evtuguin1.
Abstract
Ellagitannins (ETs), characterized by their diversity and chemical complexity, belong to the class of hydrolysable tannins that, via hydrolysis under acidic or alkaline conditions, can yield ellagic acid (EA). They are mostly found as a part of extractives in angiosperms. As known antioxidants and chelators, EA and EA derivatives are drawing an increasing interest towards extensive technical and biomedical applications. The latter ones include possible antibacterial, antifungal, antiviral, anti-inflammatory, hepato- and cardioprotective, chemopreventive, neuroprotective, anti-diabetic, gastroprotective, antihyperlipidemic, and antidepressant-like activities, among others. EA's synthesis and production challenges prompt further research on new methods and alternative sources. Conventional and prospective methods and raw materials for the production of EA and its derivatives are reviewed. Among the potential sources of EA, the residues and industrial streams of the pulp industry have been highlighted and considered as an alluring alternative in terms of commercial exploitation.Entities:
Keywords: antioxidant properties; bioavailability; biological activity; ellagic acid; ellagitannins; production routes; urolithins
Year: 2020 PMID: 32545813 PMCID: PMC7355634 DOI: 10.3390/molecules25122745
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Chemical structure of ellagic acid.
Figure 2Example of some ellagitannin structures and their precursor, β-pentagalloyl glucose.
Sources of EA and its content (mg·kg−1) in different fruits, nuts, seeds and woods *.
| Source | Latin Name | Total ET/EA # | Free EA | Ref. |
|---|---|---|---|---|
|
| ||||
| Arctic bramble |
| 3900 (fw) | - | [ |
| Blackberry |
| 1500 ± 140 (dw) | - | [ |
| Camu-camu fruit: |
| [ | ||
| Pulp powder | 258.5 ± 4.3 (dw) * | 56.0 ± 1.1 (dw) | ||
| Flour | 5656.6 ± 11.3 (dw) * | 764.9 ± 4.9 (dw) | ||
| Peel | 71.4 (fw) * | Nd | ||
| Pulp | 67.3 (fw) * | Nd | ||
| Seeds | 2819.8 (fw) * | 50.4 (fw) | ||
| Cloudberry |
| 3600 (fw) | - | [ |
| 3151 (fw) | - | [ | ||
| Cranberries |
| 120 ± 4 (dw) | - | [ |
| Guava | 57.2–306 (dw) | - | [ | |
| Kakadu plum |
| 30,510–140,250 (dw) | - | [ |
| 8796.0 ± 156.0 (dw) | 6206.0 ± 22.0 (dw) | [ | ||
| Muscadine grapes |
| 360–912 (fw) | - | [ |
| Pomegranate: |
| [ | ||
| Mesocarp | 40,595.4 ± 4434.2 (dw) | 234.2 ± 13.0 (dw) | ||
| Peel | 43,979.0 ± 394.8 (dw) | 637.7 ± 32.8 (dw) | ||
| Red raspberry |
| 1500 ± 100 (dw) | - | [ |
| 1900–2700 (fw) | - | [ | ||
| 2637–3309 (fw) | - | [ | ||
| Rose hip |
| 1096 (fw) | - | [ |
| Strawberry |
| 630 ± 90 (dw) | - | [ |
| 650–850 (fw) | - | [ | ||
| 683–853 (fw) | - | [ | ||
|
| ||||
| Pomegranate juice | - | 87–2118.3 (mg·L−1) | 2.1–7.7 (mg·L−1) | [ |
| Raspberry jam | - | 764 (fw) | - | [ |
| Strawberry jam | - | 245 (fw) | - | [ |
|
| ||||
| Pecans |
| 330 ± 0.3 (dw) | - | [ |
| Walnuts |
| 590 ± 0.3 (dw) | - | [ |
|
| ||||
| Blue gum |
| - | 500–1700 (dw) | [ |
| Common Oak |
| - | 81–228 (dw) | [ |
| Pyrenean oak |
| - | 66–219 (dw) | [ |
| Rose gum |
| - | 280–512 (dw) | [ |
| Sessile oak |
| - | 109–198 (dw) | [ |
| Sweet chestnut |
| - | 74–140 (dw) | [ |
| White oak |
| - | 132–277 (dw) | [ |
|
| ||||
| Blue gum |
| - | 471 (dw) | [ |
| (Hybrid) eucalypt |
| - | 2243–2307 (dw) | [ |
| Maidens Gum |
| - | 1130–1178 (dw) | [ |
| Oak | - | 2200–3700 (dw) | [ | |
| Sweet chestnut |
| - | 4300–9300 (dw) | [ |
| Rose Gum |
| - | 2639–2721 (dw) | [ |
|
| ||||
| Eucalypt leaves |
| 3320.0 ± 80.0 (dw) | - | [ |
| Filtrates from unbleached kraft wood |
| - | 98 ± 0.7 (mg/L) | [ |
| Sulphite spent liquor |
| - | 1165.5 (mg/L) | [ |
#—total EA after ETs hydrolysis; all values are presented as mg per kg of source (dw = dry weight or fw = full weight). *—Total ET + Total EA derivatives.
Figure 3Urolithins derived from ellagic acid and their relative bioavailability.
Figure 4In vitro radical scavenging and antioxidant capacity studies of ellagic acid (EA) vs. butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), alfa-tocopherol (alpha-T) and ascorbic acid (AA). The values are presented in percentages at the same concentrations, except for the modified FRAP test, which indicates the absorbance of the reaction mixture (adapted from [120]).
Possible biological effects of EA and its derivatives.
| Activity | Active Compound | Main Features | Ref. |
|---|---|---|---|
| Antibacterial | Commercial extract of pomegranate byproduct (POMx) and punicalagin | Inhibited the growth of pathogenic | [ |
| Antibacterial | Ellagic acid | Action against | [ |
| Antibacterial | Tellimagrandin I | Time- and dose-dependent bactericidal activity against | [ |
| Antibacterial | Ellagic acid | EA—cyclodextrin complex expressed activity against | [ |
| Antimycobacterial | Punicalagin | Inhibited the growth of | [ |
| Antileishmanial | Geraniin, phyllanthusiin B and elaeocarpusin | Exhibited effect against protozoa | [ |
| Antimalarial | Ellagic acid | [ | |
| Antibabesial | Ellagic acid | [ | |
| Antifungal | Candelitannin (ellagitannin) isolated from | Effective against | [ |
| Antifungal | Ellagic acid | Action against | [ |
| Antiviral | Castalagin, vescalagin and grandinin. | Action against acyclovir (ACV)—resistant strains of | [ |
| Prebiotic effect | Commercial extract of pomegranate byproduct (POMx) and punicalagin | Enhanced growth of | [ |
| Anti-inflammatory | Ellagic acid, gallic acid and punicalagin A&B | Potential inhibition of LPS-induced NO, PGE-2 and IL-6 production | [ |
| Anti-inflammatory | Ellagic acid | Enhancement of EA’s anti-inflammatory properties | [ |
| Treatment of Type 2 diabetes mellitus | Ellagic acid and ETs from | Inhibition of protein tyrosine phosphatases (PTP1B) | [ |
| Prevention of diabetic complications | Ellagic acid | ALR2 (aldose reductase) inhibition and antiglycating effect of EA could possibly delay progression of cataract | [ |
| Anticancerous agent | Ellagic acid | Inhibition of SphK1 (sphingosine kinase 1) | [ |
| Antiangiogenic and antiproliferative effect | Ellagic acid | Reduction in metastatic potential of bladder cancer and enhancement of the efficacy of anti-VEGF-A therapies | [ |
| Gastroprotective | Ellagitannin-rich fraction obtained from | Possibly due to their antioxidant, anti-inflammatory and anti-apoptotic properties. Partially mediated by attenuating induced oxidative stress and by the reduction of pro-inflammatory markers. | [ |
| Hepatoprotective | Ellagic acid | Suppression of caspase-3, bcl-2, NF-kB and Nrf-2 | [ |
| Antiarrhythmic | Ellagic acid | Antilipid peroxidation property and antihyperlipidemic activity through 3-hydroxy-3 methyl glutaryl CoA reductase inhibition; cardioprotective effect | [ |
| Antiasthmatic | Effective eosinophilic inflammation suppressors | [ | |
| Antihyperlipidemic | Ellagic acid | EA-CoQ10 nanoparticles effectively attenuated induced hyperlipidemia in rats | [ |
| Antiepileptic | Ellagic acid | Possibly achieved through increase of brain GABA levels | [ |
| Antianxiety | Ellagic acid | Possible involvement of GABAergic system in the anxiolytic action | [ |
| Antidepressant | Ellagic acid | Possible interaction through adrenergic and serotonergic systems or through inhibition of inducible NOS | [ |
| Neuroprotective in SAD | Ellagic acid | Diminished oxidative stress profile, pro-inflammatory markers, acetylcholinesterase activity, and amyloid-β plaque level in induced SAD (Sporadic Alzheimer’s Disease) rats | [ |
| Skin-whitening agent | Ellagic acid | EA acts as an alternative substrate of tyrosinase, inhibiting the melanogenesis process | [ |